Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure

  • Tomoaki NakataEmail author
  • Takeru Wakabayashi
  • Michifumi Kyuma
  • Toru Takahashi
  • Kazufumi Tsuchihashi
  • Kazuaki Shimamoto
Original Article



Although the benefits of treatment with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are well known, no method has as yet been established to predict the efficacy of drug therapy. This study tested whether cardiac 123I-metaiodobenzylguanidine (MIBG) activity is of prognostic value and can predict the improvement in heart failure patients resulting from treatment with ACE inhibitors and/or beta-blockers.


Following quantification of the heart-to-mediastinum ratio (HMR) of MIBG activity, 88 patients with heart failure who were treated with ACE inhibitors and/or beta-blockers (treated group) and 79 patients with heart failure who were treated conventionally without the aforementioned agents, and who served as controls, were followed up for 43 months with a primary endpoint of cardiac death.


The treated group had a significantly lower prevalence of cardiac death and a significantly lower mortality at 5 years compared with the control group (15% vs 37% and 21% vs 42%, p<0.05, respectively). Multivariate analysis revealed that significant predictors were HMR, age, nitrate use and ventricular tachycardia for the treated group, and HMR, nitrate use and NYHA class for the control group. The drug treatment significantly reduced mortality from 36% to 12% when HMR was 1.53 or more and from 53% to 37% when HMR was less than 1.53. The reduction in risk of mortality within 5 years in patients without a severe MIBG defect (67%) was twice that in patients with such a defect (32%) (p<0.05).


The reduction in mortality risk achieved by using ACE inhibitors and/or beta-blockers is associated with the severity of impairment of cardiac MIBG uptake. Cardiac MIBG activity can consequently be of long-term prognostic value in predicting the effectiveness of such treatment in patients with heart failure.


Heart failure Drug treatment Prognosis Autonomic nervous system Radionuclide imaging 



The authors are grateful to the staff of the Cardiology and Nuclear Medicine Departments, Sapporo Medical University School of Medicine, Sapporo Jun-kanki Clinic, Hokkaido Cardiovascular Hospital, and Sapporo Social Insurance General Hospital, Sapporo, Japan for their cooperation in the multicentre clinical study.


  1. 1.
    Zipes DP. Sympathetic stimulation and arrhythmias. N Engl J Med 1991;325:656–7.PubMedGoogle Scholar
  2. 2.
    Kaye D, Lefkovits J, Jennings G, et al. Adverse consequence of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257–63.CrossRefPubMedGoogle Scholar
  3. 3.
    Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471–7.PubMedGoogle Scholar
  4. 4.
    Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by metaiodobenzylguanidine in patients with failing and non-failing hearts. J Nucl Cardiol 1998;5:579–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Wakabayashi T, Nakata T, Hashimoto A, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757–67.PubMedGoogle Scholar
  7. 7.
    Pritchett AM, Redfield MM. Beta-blockers: new standard therapy for heart failure. Mayo Clin Proc 2002;77:839–45.PubMedGoogle Scholar
  8. 8.
    Hunt HA, Baker DW, Chin MH, et al. American College of Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001;104:2996–3007.PubMedGoogle Scholar
  9. 9.
    Pitt B, Poole-Wilson PA, Sega R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—losartan heart failure survival study ELITE II. Lancet 2000;355:1582–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Takeishi Y, Atsumi H, Fujiwara S, et al. ACE inhibition reduced cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085–9.PubMedGoogle Scholar
  12. 12.
    Merlet P, Pouillart F, Dubois-Rande JL, et al. Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. J Nucl Med 1999;40:224–31.PubMedGoogle Scholar
  13. 13.
    Sakata K, Shirotani M, Yoshida H, et al. Physiological fluctuation of the human left ventricle sympathetic nervous system assessed by iodine-123-MIBG. J Nucl Med 1998;39:1667–71.PubMedGoogle Scholar
  14. 14.
    Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547–52.PubMedGoogle Scholar
  15. 15.
    Nakata T, Wakabayashi T, Kyuma M, et al. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail 2003;9:113–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Inoue H, Zipes DP. Result of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation 1987;75:877–87.PubMedGoogle Scholar
  17. 17.
    Barron HV, Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 1996;27:1053–60.Google Scholar
  18. 18.
    Mitrani RD, Klein LS, Miles WM, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol 1993;22:1344–53.PubMedGoogle Scholar
  19. 19.
    Nakata T, Nagao K, Tsuchihashi K, et al. Regional cardiac sympathetic nerve dysfunction and the diagnostic efficacy of metaiodobenzylguanidine tomography in stable coronary artery disease. Am J Cardiol 1996;78:292–7.CrossRefPubMedGoogle Scholar
  20. 20.
    McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123 metaiodobenzylguanidine tomographic imaging after myocardial infarction. Am J Cardiol 1991;67:236–42.CrossRefPubMedGoogle Scholar
  21. 21.
    Tobes MC, Jaques S, Wieland DM, et al. Effect of uptake-1 inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 1985;26:897–907.PubMedGoogle Scholar
  22. 22.
    Miyazaki T, Zipes DP. Presynaptic modulation of efferent sympathetic and vagal neurotransmission in canine heart by hypoxia, high K+, low pH, and adenosine. Possible relevance to ischemia-induced denervation. Circ Res 1990;66:289–301.PubMedGoogle Scholar
  23. 23.
    Rabinovitch MA, Rose CP, Schwab AJ, et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993;34:589–600.PubMedGoogle Scholar
  24. 24.
    Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;93:1667–76.PubMedGoogle Scholar
  25. 25.
    Arora R, Ferrick KJ, Nakata T, et al. 123I-metaiodobenzylguanidine (MIBG) imaging and heart rate variability analysis to predict the need for implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121–31.CrossRefPubMedGoogle Scholar
  26. 26.
    Nagahara D, Nakata T, Uno K, et al. Cardiac metaiodobenzylguanidine activity in combination with cardiac function or plasma brain natriuretic level can predict the need for an implantable cardioverter defibrillator. Circulation 2003;108(Suppl):IV-544 [Abstract].Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Tomoaki Nakata
    • 1
    Email author
  • Takeru Wakabayashi
    • 1
  • Michifumi Kyuma
    • 1
  • Toru Takahashi
    • 1
  • Kazufumi Tsuchihashi
    • 1
  • Kazuaki Shimamoto
    • 1
  1. 1.Second Department of Internal Medicine (Cardiology)Sapporo Medical University School of MedicineSapporoJapan

Personalised recommendations